Pemvidutide

Pemvidutide is Altimmune's investigational once-weekly peptide hitting two metabolic targets at once: GLP-1 (the satiety and insulin pathway behind Ozempic and Mounjaro) and glucagon (a hormone that ramps up fat burning and energy expenditure). The company is pushing it across four indications: MASH (the fatty liver disease formerly called NASH), obesity, alcohol-associated liver disease, and alcohol use disorder. The lead asset is IMPACT (NCT05989711), a 212-patient Phase 2b in biopsy-confirmed MASH. The 24-week results, published in The Lancet in late 2025 [1], delivered a clear win: NASH resolution without worsening of fibrosis was 59.1% at the 1.2 mg dose and 52.1% at the 1.8 mg dose versus 19.1% on placebo. On the strength of those data, the FDA granted Breakthrough Therapy Designation for MASH in January 2026 [11], on top of pre-existing Fast Track designations in MASH and alcohol use disorder. 48-week IMPACT topline data announced December 2025 [12] showed continued improvement in non-invasive fibrosis markers, weight loss still ramping at the higher dose, and an End-of-Phase 2 meeting that supports a Phase 3 (PERFORMA) in MASH in H2 2026. Altimmune (NASDAQ: ALT) is a single-asset story, but a $225 million April 2026 raise put pro forma cash at $535 million, enough to self-fund into the 2029 Phase 3 readout [13]. The strategic question is whether the glucagon arm and pemvidutide's lean-mass-sparing profile differentiate against an incumbent landscape that now includes Novo's semaglutide (FDA-approved for MASH August 2025 after hitting 62.9% NASH resolution vs 34.3% placebo in ESSENCE [7]) and Madrigal's Rezdiffra.

Pemvidutide is a novel peptide, not previously approved for any indication. Altimmune has three active Phase 2 programs and a planned Phase 3 (PERFORMA in MASH, initiation H2 2026) [13]. The lead trial, IMPACT (NCT05989711) in MASH, completed enrollment in 2024, reported positive 24-week topline data in 2025 (published in The Lancet [1]) and 48-week topline data in December 2025 [12]. A separate 24-week Phase 2 in MASLD (the broader fatty liver category without confirmed steatohepatitis) was published in JHEP Reports in 2025 [2], and an earlier MASLD study appeared in J Hepatol [3]. MOMENTUM, the 48-week Phase 2 in obesity, reported topline results in 2024 and was presented at the American Diabetes Association Scientific Sessions [14]. Two new Phase 2 trials launched in 2025: RESTORE (NCT07009860) in alcohol-associated liver disease, currently recruiting at 100 patients with enrollment completion expected Q3 2026, and RECLAIM (NCT06987513) in alcohol use disorder among overweight or obese subjects, with topline data expected Q3 2026 [4][5][13]. FDA designations as of June 2026: Breakthrough Therapy Designation for MASH (granted January 5, 2026, on the basis of IMPACT 24-week data) [11], Fast Track designation for MASH, and Fast Track designation for AUD. The MASH market opened in March 2024 with Madrigal's Rezdiffra (resmetirom), the first drug approved for the indication, and expanded in August 2025 with FDA approval of Novo Nordisk's semaglutide based on the Phase 3 ESSENCE trial [7]. Pemvidutide's regulatory path requires biopsy-based endpoints (NASH resolution and fibrosis improvement) for accelerated approval, conventionally a 52-week histology readout. Altimmune disclosed in Q1 2026 results that the End-of-Phase 2 FDA meeting supports moving PERFORMA forward in MASH patients with moderate to advanced fibrosis [13].

The biology is simple in concept. GLP-1 is a gut hormone released after meals that tells the pancreas to release insulin and tells the brain you are full. Drugs that mimic GLP-1, like semaglutide (Ozempic, Wegovy), produce large weight loss because patients eat less. Glucagon is the opposite hormone of insulin: it tells the liver to release stored sugar and, more importantly for this drug, it ramps up energy expenditure and mobilizes fat. By itself, glucagon would raise blood sugar, which is bad. Combined with GLP-1's insulin-releasing effect, the glucose problem is offset, and the fat-burning benefit is preserved. The hoped-for advantage: more direct liver fat reduction than a pure GLP-1 agonist, because glucagon receptors are abundant on liver cells and signal the liver to oxidize fat rather than store it. A secondary mechanistic advantage Altimmune emphasizes is lean mass preservation: the energy-expenditure pathway means patients burn more fat per kilogram of weight lost, which is the basis of the marketing claim that pemvidutide is less catabolic for muscle than tirzepatide. This dual-agonist concept has a mixed track record. Cotadutide (AstraZeneca, same class) was dropped after underwhelming MASH data. Survodutide (Boehringer Ingelheim with Zealand Pharma, GLP-1 plus glucagon) hit its endpoints in a Phase 2 MASH trial in 2024. Efinopegdutide (Merck via Hanmi) is also in development. The mechanism is plausible and the target biology is well-understood. Pure GLP-1 (semaglutide) hit its Phase 3 MASH endpoints in the ESSENCE trial [7] and was approved August 2025, which raises rather than removes the bar for the glucagon arm: pemvidutide now has to demonstrate either superior magnitude, superior tolerability, or a meaningful body-composition differentiator to justify share against an incumbent.

IMPACT (NCT05989711) is a 212-patient, randomized, double-blind, placebo-controlled Phase 2b in adults with biopsy-confirmed MASH and fibrosis stage F2 to F3 [8]. Patients receive weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg, or placebo, for 24 weeks (with a 48-week extension). The primary endpoint is NASH resolution on biopsy: NAS ballooning score of 0, lobular inflammation of 0 or 1, and at least a 2-point NAS reduction, without worsening fibrosis. The 24-week histology results published in The Lancet [1]: NASH resolution without worsening of fibrosis was achieved in 59.1% of the 1.2 mg arm and 52.1% of the 1.8 mg arm versus 19.1% on placebo (both doses statistically significant). Conventional histologic fibrosis improvement was not the primary 24-week endpoint, but consistent reductions across non-invasive markers (ELF, PRO-C3, AST, MRI-PDFF, FibroScan, cT1, FAST) and a supplemental AI-assisted biopsy analysis showed statistically significant fibrosis reduction at 24 weeks. The 48-week topline (December 2025) [12] reported further improvement in ELF and Liver Stiffness Measurement vs placebo, continued weight loss at 1.8 mg with no plateau, and preserved tolerability. RESTORE (NCT07009860) is a 100-patient Phase 2 in alcohol-associated liver disease. Primary endpoint is relative change in liver stiffness by VCTE (vibration-controlled transient elastography, a non-invasive ultrasound-based measure of liver fibrosis) at week 24 [4]. VCTE is a screening tool, not a regulatory endpoint, so this trial generates proof-of-concept data only. RECLAIM (NCT06987513) is a 100-patient Phase 2 in alcohol use disorder among overweight or obese adults. Primary endpoint is reduction in heavy-drinking days using the Timeline Followback method [5]. GLP-1 agonists have shown anti-craving signals in alcohol and nicotine studies, so a dual agonist might extend that. Whether reducing heavy-drinking days alone is enough for an AUD approval is unclear; existing AUD drugs (naltrexone, acamprosate) typically use abstinence-related endpoints.

The model gives this drug an 8% chance of eventually being approved. It starts from a historical base rate of about 35% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The main factor pulling the number up is more secondary endpoints than usual; the main factors pulling it down are heavier-than-usual blinding, a thin or weak sponsor approval record, and weak or limited earlier-phase results. The remaining facts are close to average for this stage, so they leave the estimate roughly where the base rate set it.

Efficacy risk has narrowed but not disappeared. IMPACT 24-week histology already cleared the placebo gap convincingly (59.1% / 52.1% vs 19.1% NASH resolution), and the FDA's Breakthrough Therapy Designation is an external vote that the data are meaningful. The remaining efficacy question is whether the 52-week biopsy fibrosis endpoint in Phase 3 PERFORMA will deliver fibrosis improvement consistent with or better than semaglutide's ESSENCE numbers (NASH resolution 62.9% vs 34.3% placebo; fibrosis improvement 36.8% vs 22.4% placebo, both at 72 weeks) [7]. If pemvidutide's fibrosis number on biopsy at 52 weeks lands materially below ESSENCE, the differentiation argument compresses. Phase 2 MASH readouts have historically failed to replicate in Phase 3 (selonsertib, simtuzumab, cenicriviroc all went to zero), so a Phase 2b biopsy win is necessary but not sufficient. Safety risk is concrete and class-specific. The glucagon arm raises lean mass loss as a theoretical concern because glucagon promotes amino acid catabolism, but the MOMENTUM Phase 2 obesity data are actively reassuring: weight loss of 10.3% (1.2 mg), 11.2% (1.8 mg), and 15.6% (2.4 mg) at 48 weeks versus 2.2% on placebo, with 78.1% of weight lost as fat and only 21.9% as lean mass [14], which is favorable versus reported lean-mass loss fractions for tirzepatide and semaglutide (commonly in the 25-40% range, though direct head-to-head comparisons do not exist). A 2025 review in J Cachexia Sarcopenia Muscle named muscle loss in obesity therapy an open regulatory question [10]. GI tolerability (nausea, vomiting) is a known issue across the incretin class and at higher doses limits compliance. Execution risk is materially lower than it was. After a $225 million April 2026 public offering, Altimmune reported $332 million in cash at March 31, 2026 and $535 million pro forma at April 30, 2026, which management states funds operations through the Phase 3 MASH 52-week readout in 2029 [13]. That is enough runway to self-fund PERFORMA without an immediate dilutive deal. Commercial risk: even with positive Phase 3 data, pemvidutide would launch into a market where Rezdiffra is established in non-cirrhotic MASH and semaglutide is the GLP-1 incumbent post-2025 approval. Payers will favor cheaper, more established options. Niche positioning in ALD or AUD is a possible survival path, but those markets are smaller and reimbursement is uncertain.

This is no longer a 'wait for the readout' story. IMPACT 24-week histology is published [1], 48-week extension data have been reported [12], MOMENTUM established a real lean-mass differentiation signal in obesity [14], Breakthrough Therapy Designation is in hand [11], and Altimmune is funded through 2029 [13]. The asset has graduated from speculative Phase 2 to a credible Phase 3 candidate with a defensible niche claim (lean mass preservation) and an identified registrational trial (PERFORMA, H2 2026 start). The remaining binary is the Phase 3 52-week biopsy histology in 2029, which is far enough out that interim signals from PERFORMA and the parallel ALD and AUD programs will dominate near-term price action. Key near-term pressure points: (1) RECLAIM Phase 2 AUD topline expected Q3 2026, with the heavy-drinking-days endpoint being non-standard for AUD approvals but a clean efficacy signal one way or the other; (2) RESTORE Phase 2 ALD enrollment completion expected Q3 2026, with topline likely 2027; (3) any partnership announcement for ex-US commercialization; and (4) PERFORMA initiation and any subsequent operational disclosures (site activation, enrollment pace). The most important pemvidutide-specific question for an investor: does the lean mass preservation claim survive direct comparison data? If a head-to-head against tirzepatide or semaglutide is ever run, that is the readout that determines whether pemvidutide is a niche play or a real category contender. The 29% PoS captures meaningful upside without ignoring that Phase 3 MASH is where prior drugs have died and that the commercial environment in 2029 will be more crowded than it is now.